Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice TargetHot
Leerink Partners analyst David Risinger maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Market Perform and raises the price target from $835 to $997.
Leerink Partners analyst David Risinger maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Market Perform and raises the price target from $835 to $997.